GlassScriptPhysician profile
Gerard Diefes
NPI 1417948951
$9,623.65
in general payments reported to CMS, 2019-2025
32 companies · $2,981 in 2025
The $2,981 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,730 · 2020: $238 · 2021: $1,120 · 2022: $1,210 · 2023: $1,117 · 2024: $1,228 · 2025: $2,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,052 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,052.12 |
| Education | $272.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,118.58 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,562.07 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $837.24 | 2019-2025 | Dupixent |
| Insmed, INC. | $667.21 | 2019-2024 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $520.40 | 2019-2022 | |
| Genzyme Corporation | $476.81 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $442.55 | 2019-2025 | |
| Harmony Biosciences LLC | $389.21 | 2021-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.11 | 2019-2025 | Jascayd, Stiolto Respimat, Ofev |
| Sanofi-Aventis U.S. LLC | $230.56 | 2021-2025 | |
| Axsome Therapeutics, INC. | $230.18 | 2023-2025 | Sunosi |
| Mallinckrodt Hospital Products INC. | $195.73 | 2020-2025 | Acthar |
| Genentech USA, INC. | $184.86 | 2019-2023 | Xolair |
| Pulmonx Corporation | $156.24 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Verona Pharma, INC. | $155.15 | 2025 | Ohtuvayre |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $141.71 | 2019-2025 | Vest Therapy Und |
| Daiichi Sankyo INC. | $123.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $113.83 | 2020-2022 | |
| Advanced Respiratory, INC | $106.78 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $94.45 | 2019 | |
| Viatris Specialty LLC | $93.99 | 2025 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $85.96 | 2021 | |
| Mylan Specialty L.P. | $85.49 | 2019-2024 | Yupelri |
| Paratek Pharmaceuticals, INC. | $80.39 | 2023-2025 | Nuzyra |
| Mallinckrodt Enterprises LLC | $38.13 | 2019 | |
| Amgen INC. | $36.14 | 2022 | |
| Circassia INC. | $31.50 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $27.23 | 2025 | Lumryz |
| United Therapeutics Corporation | $24.60 | 2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $22.16 | 2022 | |
| Electromed, INC. | $16.65 | 2023 | Smartvest |
| Grifols USA, LLC | $14.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Diefes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.